Models for prevention and treatment of cancer: Problems vs promises

Biochemical Pharmacology

Volumn 78, Issue 9, 2009, Pages 1083-1094

  Aggarwal, Bharat B ^a   Danda, Divya ^a   Gupta, Shan ^a   Gehlot, Prashasnika ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Cell signaling; Pathogenesis; Therapeutic targets

Indexed keywords

AFLATOXIN B1; ALCOHOL; ALPHA TOCOPHEROL; BEVACIZUMAB; BORTEZOMIB; C 255; CA 125 ANTIGEN; CELECOXIB; CETUXIMAB; DASATINIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LENALIDOMIDE; NILOTINIB; ONCOPROTEIN; PANITUMUMAB; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RITUXIMAB; SELENIUM; SORAFENIB; SUNITINIB; TOBACCO SMOKE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLEDRONIC ACID; ZOMETRA;

ABDOMINAL PAIN; ACNE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOMATOUS POLYP; ADJUVANT THERAPY; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANEUPLOIDY; ANOREXIA; ARM EDEMA; ARTICLE; ASTHENIA; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CARDIOMYOPATHY; CHRONIC MYELOID LEUKEMIA; CIGARETTE SMOKING; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; COUGHING; CYTOPENIA; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG APPROVAL; DRUG TARGETING; DRY SKIN; DYSPEPSIA; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; ENVIRONMENTAL FACTOR; EXPERIMENTAL MODEL; EYE IRRITATION; FATIGUE; FEVER; FLATULENCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ENGINEERING; GLOSSODYNIA; HAIR COLOR; HAIR DISEASE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEADACHE; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEARTBURN; HEPATITIS; HEPATITIS B; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOTHYROIDISM; INDIGESTION; INDIVIDUALIZATION; INFECTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY CARCINOMA; KIDNEY DISEASE; LEG EDEMA; LEUKOPENIA; LIFESTYLE MODIFICATION; LIMB PAIN; LIVER CELL CARCINOMA; LIVER INJURY; LUNG DISEASE; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MEDICAL SOCIETY; MENTAL DISEASE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE CRAMP; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEURALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OFF LABEL DRUG USE; OVARY CANCER; PANCREAS CANCER; PATIENT CARE; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; PRURITUS; QUALITY OF LIFE; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SINUSITIS; SKIN DISCOLORATION; SKIN DISEASE; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STOMACH PAIN; STOMACH ULCER; STOMATITIS; SWELLING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR LYSIS SYNDROME; ULTRAVIOLET RADIATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEAKNESS; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MODELS, THEORETICAL; NEOPLASMS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 68849085858     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.027     Document Type: Note

References (124)

1. Garodia P., Ichikawa H., Malani N., Sethi G., and Aggarwal B.B. From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol 5 (2007) 25-37
2. Hernando E. Cancer. Aneuploidy advantages?. Science (New York, NY) 322 (2008) 692-693
3. Nambiar M., Kari V., and Raghavan S.C. Chromosomal translocations in cancer. Biochim Biophys Acta 1786 (2008) 139-152
4. Bodmer W., and Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40 (2008) 695-701
5. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., et al. A census of human cancer genes. Nat Rev Cancer 4 (2004) 177-183
6. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
7. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science (New York, NY) 314 (2006) 268-274
8. Fleming J.L., Huang T.H., and Toland A.E. The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res 68 (2008) 9116-9121
9. Masters J.R. HeLa cells 50 years on: the good, the bad and the ugly. Nat Rev Cancer 2 (2002) 315-319
10. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48 (1988) 4827-4833
11. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace Jr. A.J., Kohn K.W., et al. An information-intensive approach to the molecular pharmacology of cancer. Science (New York, NY) 275 (1997) 343-349
12. Monks A., Scudiero D.A., Johnson G.S., Paull K.D., and Sausville E.A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des 12 (1997) 533-541
13. Arlett C.F. The use of dubious cell lines in research: is trust enough?. Lancet Oncol 2 (2001) 467
14. van Helden P.D., Wiid I.J., Albrecht C.F., Theron E., Thornley A.L., and Hoal-van Helden E.G. Cross-contamination of human esophageal squamous carcinoma cell lines detected by DNA fingerprint analysis. Cancer Res 48 (1988) 5660-5662
15. Pathak S., Jaison J., and Basu S.K. Merkel cell carcinoma: a case report. Indian J Pathol Microbiol 50 (2007) 325-326
16. Nelson-Rees W.A., Daniels D.W., and Flandermeyer R.R. Cross-contamination of cells in culture. Science (New York, NY) 212 (1981) 446-452
17. Goldenberg D.M., and Pavia R.A. Malignant potential of murine stromal cells after transplantation of human tumors into nude mice. Science (New York, NY) 212 (1981) 65-67
18. Lacroix M. MDA-MB-435 cells are from melanoma, not from breast cancer. Cancer Chemother Pharmacol 63 3 (2009) 567
19. Pathak S., Nemeth M.A., Multani A.S., Thalmann G.N., von Eschenbach A.C., and Chung L.W. Can cancer cells transform normal host cells into malignant cells?. Br J Cancer 76 (1997) 1134-1138
20. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2 (2003) S134-S139
21. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40 (2004) 827-836
22. Kucherlapati R., Lin D.P., and Edelmann W. Mouse models for human familial adenomatous polyposis. Semin Cancer Biol 11 (2001) 219-225
23. Feitsma H., and Cuppen E. Zebrafish as a cancer model. Mol Cancer Res 6 (2008) 685-694
24. Kung A.L. Practices and pitfalls of mouse cancer models in drug discovery. Adv Cancer Res 96 (2007) 191-212
25. Giovanella B.C., Yim S.O., Stehlin J.S., and Williams Jr. L.J. Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. J Natl Cancer Inst 48 (1972) 1531-1533
26. Venditti J.M., Wesley R.A., and Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 20 (1984) 1-20
27. Von Hoff D.D. There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4 (1998) 1079-1086
28. Desai K.V., Xiao N., Wang W., Gangi L., Greene J., Powell J.I., et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 99 (2002) 6967-6972
29. Isayeva T., Chanda D., Kallman L., Eltoum I.E., and Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67 (2007) 5789-5797
30. Alexander J. Use of transgenic mice in identifying chemopreventive agents. Toxicol Lett 112-113 (2000) 507-512
31. Hursting S.D., Perkins S.N., Haines D.C., Ward J.M., and Phang J.M. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 55 (1995) 3949-3953
32. Kavanaugh C., and Green J.E. The use of genetically altered mice for breast cancer prevention studies. J Nutr 133 (2003) 2404S-2409S
33. Lipkin M., Yang K., Edelmann W., Xue L., Fan K., Risio M., et al. Preclinical mouse models for cancer chemoprevention studies. Ann N Y Acad Sci 889 (1999) 14-19
34. Fiebig H.H., Maier A., and Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40 (2004) 802-820
35. Burchill S.A. What do, can and should we learn from models to evaluate potential anticancer agents?. Future Oncol 2 (2006) 201-211
36. Hollingshead M.G. Antitumor efficacy testing in rodents. J Natl Cancer Inst 100 (2008) 1500-1510
37. Voskoglou-Nomikos T., Pater J.L., and Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9 (2003) 4227-4239
38. Greaves P., Williams A., and Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev 3 (2004) 226-236
39. Schein P.S., Davis R.D., Carter S., Newman J., Schein D.R., and Rall D.P. The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin Pharmacol Ther 11 (1970) 3-40
40. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32 (2000) 56-67
41. Srinivas P.R., Kramer B.S., and Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol 2 (2001) 698-704
42. Schmidt C. Urine biomarkers may someday detect even distant tumors. J Natl Cancer Inst 101 (2009) 8-10
43. Le Tourneau C., Faivre S., and Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev 34 (2008) 37-48
44. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
45. Douillard J.Y., Tilleul P., Ychou M., Dufour P., Perrocheau G., Seitz J.F., et al. Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting. Oncology 72 (2007) 248-254
46. Hirsch F.R. EGFR inhibitors in the treatment of lung cancer. Onkologie 30 (2007) 476
47. Jubb A.M., Hurwitz H.I., Bai W., Holmgren E.B., Tobin P., Guerrero A.S., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
48. Bukowski R., Cella D., Gondek K., and Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30 (2007) 220-227
49. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321 (2008) 1807-1812
50. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 321 (2008) 1801-1806
51. Clarke A.R., and Meniel V. The intestinal stem cell niche studied through conditional transgenesis. Ernst Schering Found. Symp Proc (2006) 99-108
52. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N Engl J Med 355 (2006) 1253-1261
53. Schmidt C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J Natl Cancer Inst 100 (2008) 694-695
54. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., and Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 456 (2008) 593-598
55. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
56. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
57. Dalerba P., and Clarke M.F. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1 (2007) 241-242
58. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68 (2008) 3243-3250
59. Baker R. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration. Beta (1998) 8-9
60. Csermely P., Agoston V., and Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26 (2005) 178-182
61. Keith C.T., Borisy A.A., and Stockwell B.R. Multicomponent therapeutics for networked systems. Nature reviews 4 (2005) 71-78
62. Mayer R.J. Targeted therapy for advanced colorectal cancer-more is not always better. N Engl J Med 360 (2009) 623-625
63. de Jonge M.J., and Verweij J. Multiple targeted tyrosine kinase inhibition in the clinic, all for one or one for all?. Eur J Cancer 42 (2006) 1351-1356
64. George D., and Verweij J. Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'. Ann Oncol 18 Suppl. 10 (2007) x1-x2
65. Borisy A.A., Elliott P.J., Hurst N.W., Lee M.S., Lehar J., Price E.R., et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 100 (2003) 7977-7982
66. Zimmermann G.R., Lehar J., and Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12 (2007) 34-42
67. Aggarwal B.B., and Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30 (2009) 85-94
68. Harikumar K.B., and Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7 (2008) 1020-1035
69. Shishodia S., Harikumar K.B., Dass S., Ramawat K.G., and Aggarwal B.B. The guggul for chronic diseases: ancient medicine, modern targets. Anticancer Res 28 (2008) 3647-3664
70. Agarwal R., Agarwal C., Ichikawa H., Singh R.P., and Aggarwal B.B. Anticancer potential of silymarin: from bench to bed side. Anticancer Res 26 (2006) 4457-4498
71. Gokmen-Polar Y., and Miller K.D. Redefining the target again: chemotherapeutics as vascular disrupting agents?. Cancer Cell 14 (2008) 195-196
72. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
73. Wang C.Y., Cusack Jr. J.C., Liu R., and Baldwin Jr. A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5 (1999) 412-417
74. Ma J., and Waxman D.J. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7 (2008) 3670-3684
75. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14 (2008) 263-273
76. Aggarwal B.B., Sethi G., Baladandayuthapani V., Krishnan S., and Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem 102 (2007) 580-592
77. Goldstein D.M., Gray N.S., and Zarrinkar P.P. High-throughput kinase profiling as a platform for drug discovery. Nat Rev 7 (2008) 391-397
78. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 12 (1965) 394-407
79. Masui H., Kawamoto T., Sato J.D., Wolf B., Sato G., and Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44 (1984) 1002-1007
80. Bareschino M.A., Schettino C., Troiani T., Martinelli E., Morgillo F., and Ciardiello F. Erlotinib in cancer treatment. Ann Oncol 18 Suppl. 6 (2007) vi35-vi41
81. Campiglio M., Normanno N., and Menard S. Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 96 9 (2004) 715-796 [author reply]
82. Krol J., Francis R.E., Albergaria A., Sunters A., Polychronis A., Coombes R.C., et al. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 6 (2007) 3169-3179
83. Gridelli C., Ardizzoni A., Ciardiello F., Hanna N., Heymach J.V., Perrone F., et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 3 (2008) 430-440
84. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
85. Yamasaki F., Zhang D., Bartholomeusz C., Sudo T., Hortobagyi G.N., Kurisu K., et al. Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. Mol Cancer Ther 6 (2007) 2168-2177
86. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
87. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 (2004) 5355-5362
88. Lazaridis G., Pentheroudakis G., and Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 66 (2008) 31-41
89. Nahta R., Yuan L.X., Du Y., and Esteva F.J. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6 (2007) 667-674
90. Barok M., Isola J., Palyi-Krekk Z., Nagy P., Juhasz I., Vereb G., et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6 (2007) 2065-2072
91. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (2000) 443-446
92. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
93. Tanner M., Jarvinen P., and Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 61 (2001) 5345-5348
94. Cardoso F., Piccart M.J., Durbecq V., and Di Leo A. Resistance to trastuzumab: a necessary evil or a temporary challenge?. Clin Breast Cancer 3 (2002) 247-257 [discussion 58-9]
95. Nahta R., Takahashi T., Ueno N.T., Hung M.C., and Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64 (2004) 3981-3986
96. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
97. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10 (2004) 5650-5655
98. Varchetta S., Gibelli N., Oliviero B., Nardini E., Gennari R., Gatti G., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67 (2007) 11991-11999
99. Mazouni C., Hall A., Broglio K., Fritsche H., Andre F., Esteva F.J., et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 109 (2007) 496-501
100. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
101. Duvic M., and Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16 (2007) 1111-1120
102. Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 108 (2008) 261-266
103. Flaherty K.T. Sorafenib in renal cell carcinoma. Clin Cancer Res 13 (2007) 747s-752s
104. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
105. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., Heim W., Berlin J., Holmgren E., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
106. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 (2006) 1779-1802
107. Holden S.N., Eckhardt S.G., Basser R., de Boer R., Rischin D., Green M., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16 (2005) 1391-1397
108. Kindler H.L., Friberg G., Singh D.A., Locker G., Nattam S., Kozloff M., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
109. Scappaticci F.A., Fehrenbacher L., Cartwright T., Hainsworth J.D., Heim W., Berlin J., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91 (2005) 173-180
110. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57 (2006) 33-47
111. Voorhees P.M., and Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46 (2006) 189-213
112. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
113. Tol J., Koopman M., Cats A., Rodenburg C.J., Creemers G.J., Schrama J.G., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
114. Dunn B.K., Ryan A., and Ford L.G. Selenium and Vitamin E Cancer Prevention Trial: a nutrient approach to prostate cancer prevention. Recent Results Cancer Res 181 (2009) 183-193
115. Yeatman T.J., Mule J., Dalton W.S., and Sullivan D. On the eve of personalized medicine in oncology. Cancer Res 68 (2008) 7250-7252
116. Lesko L.J. Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther 81 (2007) 807-816
117. Olopade O.I., Grushko T.A., Nanda R., and Huo D. Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14 (2008) 7988-7999
118. Compton C. Getting to personalized cancer medicine: taking out the garbage. Cancer 110 (2007) 1641-1643
119. Madhavan S., Zenklusen J.C., Kotliarov Y., Sahni H., Fine H.A., and Buetow K. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7 (2009) 157-167
120. Radley D.C., Finkelstein S.N., and Stafford R.S. Off-label prescribing among office-based physicians. Arch Intern Med 166 (2006) 1021-1026
121. Leveque D. Off-label use of anticancer drugs. Lancet Oncol 9 (2008) 1102-1107
122. Mathews M.S., Linskey M.E., Hasso A.N., and Fruehauf J.P. The effect of bevacizumab (Avastin) on neuroimaging of brain metastases. Surg Neurol 70 53 (2008) 649-652 [discussion 53]
123. Gant T.W., Zhang S.D., and Taylor E.L. Novel genomic methods for drug discovery and mechanism-based toxicological assessment. Curr Opin Drug Discov Dev 12 (2009) 72-80
124. Molina J.R., Yang P., Cassivi S.D., Schild S.E., and Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83 May (5) (2008) 584-594